Revvity, Inc. provides health sciences solutions, technologies, and services. It offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training, and services. The company also provides instruments, reagents, assay platforms, and software for early detection of common and rare conditions, including pregnancy and early childhood conditions, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. Revvity develops technologies supporting genomic workflows, including protein-coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under numerous brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revvity to Acquire Human Cell Design for Metabolic Drug Discovery
Revvity, Inc. has announced a definitive agreement to acquire Human Cell Design, a France-based biotechnology company specializing in human cell models for diabetes, obesity, and other metabolic diseases. The acquisition will add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026, subject to customary closing conditions and regulatory approvals; additional terms were not disclosed. Revvity's CEO Prahlad Singh highlighted that HCD's differentiated human cell models complement Revvity's screening, detection, and analysis capabilities, offering more integrated solutions. HCD's flagship EndoC-βH5 model and NatLine platform will be combined with Revvity's HTRF, AlphaLISA, and pHSense technologies, and the deal also extends to regenerative medicine and quality control applications for cell-based therapies.
Revvity raises 2026 organic growth outlook to 4-5% and adjusted EPS to $5.30-$5.40
Revvity raised its full-year 2026 guidance, now expecting total company organic growth of 4% to 5% and adjusted earnings per share of $5.30 to $5.40, up from its prior outlook of 3% to 4% growth and $5.20 to $5.30. The company reported second-quarter pro forma organic growth of 3% on total revenue of $711 million, with adjusted EPS of $1.41 well above the high end of its guidance, driven partly by $16 million in tariff-related refunds and favorable tax timing. Diagnostics revenue grew 11% organically to $352 million, while Life Sciences revenue declined 3% organically to $359 million, weighed down by an approximately 20% decline in Signals software. Management cited a progressively larger increase in orders directly related to AI and a higher-than-normal instrument backlog exiting the quarter, with double-digit growth in high-content screening. The company also signed a definitive agreement for the divestiture of its China immunodiagnostics business, expected to close by the end of 2027.
Revvity second-quarter profit falls to $51.8 million
Revvity, Inc. reported a drop in second-quarter profit. The company's bottom line totaled $51.820 million, or $0.47 per share, compared with $53.948 million, or $0.51 per share, in the same period last year. Excluding items, adjusted earnings were $1.41 per share. Revenue rose 1.3% to $729.688 million from $720.284 million a year earlier.
Revvity to report earnings Tuesday after missing revenue estimates last quarter
Life sciences company Revvity will report earnings Tuesday before the bell. Last quarter, Revvity missed analysts' revenue expectations, reporting revenues of $686.9 million, up 9.3% year on year, with full-year revenue and EPS guidance significantly below estimates. For this quarter, analysts expect revenue to grow 3.9% year on year, a reversal from the 1.6% decline in the same quarter last year. Peers Avantor and Thermo Fisher have already reported Q2 results, with Avantor posting flat revenue that beat expectations by 4.9% and Thermo Fisher reporting a 10.5% revenue increase that topped estimates by 2.4%. Revvity's stock price was unchanged over the last month and heads into earnings with an average analyst price target of $117.13 compared to the current share price of $112.52.
Revvity develops high-throughput T-SPOT A201 platform for latent TB testing
Revvity announced the development of the T-SPOT A201, a next-generation high-throughput automated platform for latent tuberculosis testing targeted for launch in the second half of 2027. The platform is designed to process up to 384 samples per instrument during an eight-hour shift with only 45 seconds of hands-on time per sample, building on the success of the Auto-Pure 2400 liquid handler. Revvity shares gained 2.4% following the announcement, and the stock has risen 16.9% year to date, outperforming the industry's 1.8% decline and the S&P 500's 7.4% gain. The U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and grow at a CAGR of 5.3% through 2035, according to Precedence Research. Revvity currently carries a Zacks Rank of 5, or Strong Sell.
High-throughput Screening Market to Reach USD 45.90 Billion by 2031
The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.
Waters Corporation Leads Research Tools and Consumables Stocks in Q1 Earnings
Waters Corporation delivered the strongest first-quarter performance among the ten research tools and consumables stocks tracked, with revenues of $1.27 billion, up 91.5% year on year and beating analysts' estimates by 4.5%. The company also posted the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Avantor reported revenues of $1.58 billion, flat year on year but exceeding expectations by 2.7%, while Revvity's revenues of $686.9 million, up 9.3% year on year, fell short of estimates by 2.6% and came with full-year guidance that missed expectations. Sotera Health Company posted revenues of $280 million, up 10% year on year and topping estimates by 3.6%, and Bio-Techne reported revenues of $311.4 million, down 1.5% year on year and missing estimates by 1.6%. Overall, the group's revenues beat consensus estimates by 1.3%, and next-quarter revenue guidance was 2% above expectations, with share prices up 22.5% on average since the latest earnings results.
South Korea automated liquid handling system market to reach $51 million by 2036
The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.
Research tools and consumables stocks report mixed Q1 with revenues beating estimates by 1.3%
The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.
Revvity Faces Slow Growth, Margin Pressure, and EPS Decline
Revvity's stock has returned 14.9% over the past six months, outperforming the S&P 500 by 5.6% and reaching $112.79 per share, but analysts highlight three reasons to avoid the stock. Organic revenue growth averaged just 2.9% annually over the last two years, lagging the sector and signaling weak core demand. Adjusted operating margin shrank by 6 percentage points over five years to 27%, while earnings per share fell 14.7% annually over the same period, outpacing revenue declines due to a rigid cost base. With shares trading at 20.3 times forward earnings, the firm suggests better opportunities exist elsewhere, including a dominant aerospace company.
Revvity launches Signals AI agentic framework on its Signals One platform
Revvity has launched Signals AI, a native agentic framework embedded within its Signals One platform that lets scientists interact with R&D data using natural language. The tool transforms experimental, instrument, and system-generated data into insights and actionable outcomes, combining modern AI reasoning with domain-specific ontologies and validated algorithms to deliver traceable, context-aware responses. Select capabilities are available now, with further enhancements expected in the coming weeks. Revvity shares fell 1% on the day of the announcement, though the stock is up 2.3% year-to-date against a 7.8% decline for its industry.
USA